Erratum: CPT 2020 and 2021 COVID-19 Tests and Vaccines Codes: A Summary
CPT Assistant, June 2021, Volume 31, Issue 6, page 11
In the May 2021 issue of CPT® Assistant, the article, "CPT 2020 and 2021 COVID-19 Tests and Vaccines Codes: A Summary" on pages 3-7 incorrectly included the Food and Drug Administration (FDA) approval pending symbol (
) for a few of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease 2019 [COVID-19]) vaccine codes, indicating that these vaccines have not yet been approved for use. The FDA has granted Emergency Use Authorization (EUA) for the Pfizer (91300), Moderna (91301), and Janssen (91303) vaccines. Therefore, the symbol should be removed from these Current Procedural Terminology (CPT®) vaccine codes.
The AstraZeneca (91302) and Novavax (91304) vaccines have not yet received the EUA; therefore, the symbol preceding these codes is correct. In addition, the viral particle number (5x1010) for codes 91302 and 91303 was incorrectly typeset, ie, it should have been superscripted. The corrected codes should appear as follows:
Vaccines, Toxoids
(Report 91300 with administration codes 0001A, 0002A)
(Report 91301 with administration codes 0011A, 0012A)(Report 91302 with administration codes 0021A, 0022A)(Report 91303 with administration code 0031A)(Report 91304 with administration codes 0041A, 0042A)When the FDA grants EUA for the AstraZeneca and Novavax vaccines, the symbol will be removed from these vaccine codes, as appropriate.
On page 5, a parenthetical note after the immunization administration for vaccines/toxoids guidelines was typeset incorrectly as guidelines. The corrected parenthetical note should be as follows.
Immunization Administration for Vaccines/Toxoids
Report 0001A, 0002A, 0011A, 0012A, 0021A, 0022A, 0031A, 0041A, 0042A for immunization administration of SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines only. Each administration code is specific to each individual vaccine product (eg, 91300, 91301, 91302, 91303, 91304), the dosage schedule (eg, first dose, second dose), and counseling, when performed. The appropriate administration code is chosen based on the type of vaccine and the specific dose number the patient receives in the schedule. For example, 0012A is reported for the second dose of vaccine 91301. Do not report 90460-90474 for the administration of SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines. Codes related to SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine administration are listed in Appendix Q, with their associated vaccine code descriptors, vaccine administration codes, vaccine manufacturer, vaccine name(s), National Drug Code (NDC) Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code descriptor and must be the vaccine represented by the manufacturer and vaccine name listed in Appendix Q.
(Do not report 90460, 90461 in conjunction with 91300, 91301, 91302, 91303, 91304 unless both a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine/toxoid product and at least one vaccine/toxoid product from 90476-90749 are administered at the same encounter) 
No comments:
Post a Comment